Response evaluation after primary systemic therapy of @entity1722 positive XXXX - an observational cross-sectional study.

@entity1 @entity0 @entity419 @entity5 @entity2286 @entity3907 @entity1722
AIM: To evaluate (I) trastuzumab-containing primary systemic therapy (PST) in @entity1 @entity1722 ( @entity1722 ) overexpressing @entity0 .; (II) compare the @entity1 who achieved and those who did not achieve pathological complete remission (pCR), and (III) analyze the accuracy of different clinical-imaging modalities in @entity5 response monitoring. METHODS: 188 @entity1 who received PST between 2008 and 2014 were reviewed and 43 @entity1722 overexpressing @entity0 @entity1 (28 Luminal B/ @entity1722 -positive and 15 @entity1722 -positive) were enrolled. 26 @entity1 received mostly @entity3907 -based PST without trastuzumab (Group 1) and 17 @entity1 received trastuzumab-containing PST (Group 2). We compared the concordance between pCR and complete remission (CR) defined by breast-ultrasound, CR defined by standard @entity419 positron emission tomography and computerized tomography (FDG-PET/CT) criteria (Method 1) and CR defined by a novel, @entity0 specific FDG-PET/CT criteria (Method 2). Sensitivity (sens), specificity (spec), and positive ( @entity2286 ) and negative predictive values (NPV) were calculated. RESULTS: Ten @entity1 (38.5%) in Group 1 and eight (47%) in Group 2 achieved pCR. pCR was significantly more frequent in @entity1722 -positive than in Luminal B/ @entity1722 -positive @entity5 in both Group 1: (P=0.043) and Group 2: (P=0.029). PET/CT evaluated by the @entity0 specific criteria (Method 2) differentiated pCR from non-pCR more accurately in both groups (Group 1: sens=77.8%, spec=%, @entity2286 =100%, NPV=71.4%; Group 2: sens=87.5%, spec=62.5%, @entity2286 =70%, NPV=83.3%) than standard PET/CT criteria (Method 1) (Group 1: sens=22.2% spec=100% @entity2286 =100% NPV=41.7%; in Group 2: sens=37.5%, spec=87.5%, @entity2286 =75% NPV=58.3%) or breast ultrasound (Group 1, sens=83.3% spec=25% @entity2286 =62.5% NPV=50%; Group 2, sens=100% spec=12.5% @entity2286 =41.6% NPV=100%). CONCLUSION: The benefit of targeted treatment with trastuzumab-containing PST in @entity1722 overexpressing @entity0 was defined in terms of pCR rate. Luminal B/ @entity1722 -positive subtype needs further subdivision to identify @entity1 who would benefit from PST. Combined evaluation of @entity5 response by our novel, @entity0 specific FDG-PET/CT criteria accurately differentiated pCR from non-pCR @entity1 .
